SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma

• Главные авторы: Xianglai Xu (Автор), Jinglai Lin (Автор), Jiahao Wang (Автор), Ying Wang (Автор), Yanjun Zhu (Автор), Jiajun Wang (Автор), Jianming Guo (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

ABSTRACTClinical guidelines have recently advised combination therapy involving immunotherapy (IO) and tyrosine kinase inhibitors (TKI) as the first-line therapy approach for advanced renal cell carcinoma (RCC). Nevertheless, there is currently no available biomarker that can effectively distinguish...